UA124922C2 - Модулятори ядерного транспорту та їх застосування - Google Patents

Модулятори ядерного транспорту та їх застосування

Info

Publication number
UA124922C2
UA124922C2 UAA201710733A UAA201710733A UA124922C2 UA 124922 C2 UA124922 C2 UA 124922C2 UA A201710733 A UAA201710733 A UA A201710733A UA A201710733 A UAA201710733 A UA A201710733A UA 124922 C2 UA124922 C2 UA 124922C2
Authority
UA
Ukraine
Prior art keywords
applications
nuclear transport
transport modulators
compounds
formula
Prior art date
Application number
UAA201710733A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вінсент П. Санданаяка
Шерон Шехтер
Шерон Шачам
Діляра МакКолі
Еркан Балоглу
Original Assignee
Біоген Ма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA124922(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Біоген Ма Інк. filed Critical Біоген Ма Інк.
Publication of UA124922C2 publication Critical patent/UA124922C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201710733A 2012-05-09 2013-05-09 Модулятори ядерного транспорту та їх застосування UA124922C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644802P 2012-05-09 2012-05-09
US201361798188P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UA124922C2 true UA124922C2 (uk) 2021-12-15

Family

ID=49448240

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201413015A UA118085C2 (uk) 2012-05-09 2013-05-09 Модулятори ядерного транспорту та їх застосування
UAA201710733A UA124922C2 (uk) 2012-05-09 2013-05-09 Модулятори ядерного транспорту та їх застосування

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201413015A UA118085C2 (uk) 2012-05-09 2013-05-09 Модулятори ядерного транспорту та їх застосування

Country Status (32)

Country Link
US (10) US9266843B2 (OSRAM)
EP (3) EP3663291B1 (OSRAM)
JP (5) JP6195909B2 (OSRAM)
KR (5) KR20200115688A (OSRAM)
CN (1) CN104428295B (OSRAM)
AU (5) AU2013259384B2 (OSRAM)
BR (1) BR112014027860B8 (OSRAM)
CA (1) CA2872190C (OSRAM)
CL (1) CL2014003054A1 (OSRAM)
CO (1) CO7190242A2 (OSRAM)
CY (2) CY1120832T1 (OSRAM)
DK (2) DK3404027T3 (OSRAM)
EA (1) EA036639B1 (OSRAM)
ES (3) ES3016982T3 (OSRAM)
GE (1) GEP20237477B (OSRAM)
HR (2) HRP20181838T1 (OSRAM)
HU (2) HUE040427T2 (OSRAM)
IN (1) IN2014DN09434A (OSRAM)
LT (2) LT3404027T (OSRAM)
ME (1) ME03795B (OSRAM)
MX (1) MX364992B (OSRAM)
NZ (1) NZ702663A (OSRAM)
PE (1) PE20150128A1 (OSRAM)
PL (2) PL3404027T3 (OSRAM)
PT (2) PT2858991T (OSRAM)
RS (2) RS58058B1 (OSRAM)
SG (1) SG11201407268SA (OSRAM)
SI (2) SI3404027T1 (OSRAM)
SM (2) SMT202000347T1 (OSRAM)
UA (2) UA118085C2 (OSRAM)
WO (1) WO2013170068A2 (OSRAM)
ZA (1) ZA202004892B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
AU2012207565B2 (en) 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
WO2013019561A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
DK3333164T3 (da) 2011-07-29 2023-09-18 Karyopharm Therapeutics Inc Hydrazide containing nuclear transport modulators and uses thereof
WO2013170068A2 (en) 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
BR112015016793B1 (pt) 2013-01-15 2021-12-28 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
HUE042800T2 (hu) 2013-06-21 2019-07-29 Karyopharm Therapeutics Inc 1,2,4-triazolok mint nukleáris transzport modulátorok és ezek alkalmazása
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
EP3143627B1 (en) * 2014-05-13 2018-07-11 QSA Global Inc. Device and method for enhanced iridium gamma radiation sources
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
AU2015301484B2 (en) 2014-08-15 2020-02-20 Karyopharm Therapeutics Inc. Polymorphs of selinexor
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017035116A1 (en) * 2015-08-25 2017-03-02 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
MA43530A (fr) * 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
EP3423468A4 (en) * 2016-02-29 2019-10-23 Ohio State Innovation Foundation AZA PEPTIDE ALDEHYDE AND KETONE
CA3013799A1 (en) * 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
EP3448234A4 (en) 2016-04-30 2019-05-01 Envision Diagnostics, Inc. MEDICAL DEVICES, SYSTEMS AND METHODS FOR PERFORMING EYE EXAMINATIONS AND EYES TRACKING
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MX2020007479A (es) 2018-01-10 2020-11-24 Xwpharma Ltd Profármacos de ketamina, composiciones y usos de los mismos.
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
WO2020117772A1 (en) 2018-12-06 2020-06-11 Biogen Ma Inc. Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
CN109928939A (zh) * 2019-02-27 2019-06-25 上海卡洛化学有限公司 一种2,2,6,6-四甲基吗啉的制备方法
AU2020266170A1 (en) * 2019-05-01 2021-11-25 Karyopharm Therapeutics Inc. Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XP01 inhibitors
CN111145135B (zh) * 2019-12-30 2021-08-10 腾讯科技（深圳）有限公司 一种图像去扰处理方法、装置、设备及存储介质
WO2022209477A1 (ja) 2021-04-01 2022-10-06 アルプスアルパイン株式会社 操作検出装置
CN117881394A (zh) 2021-08-13 2024-04-12 凯瑞康宁生物工程（武汉）有限公司 氯胺酮衍生物的药物组合物和口服剂型
TWI857509B (zh) * 2022-03-07 2024-10-01 高雄醫學大學 用於治療 ｂ 型肝炎病毒感染的方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CA2205998C (en) 1994-11-23 2002-07-16 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
EP0858457A1 (de) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
AU2178497A (en) 1996-04-04 1997-10-29 Shionogi & Co., Ltd. Cephem compounds and drugs containing the compounds
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE69723267T2 (de) 1996-04-25 2004-04-22 Nissan Chemical Industries, Ltd. Ethylenderivate und pestizide
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
JP2004509941A (ja) 2000-09-29 2004-04-02 プロリフィクス　リミテッド Ｈｄａｃインヒビターとしてのアミド結合を含むカルバミン酸化合物
JP3608050B2 (ja) 2001-07-24 2005-01-05 トヨタ自動車株式会社 ロールオーバ判別装置
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
CN101723900B (zh) 2004-05-26 2012-08-22 卫材R&D管理有限公司 肉桂酰胺类化合物
US7902367B2 (en) 2004-08-11 2011-03-08 Kyorin Pharmaceutical Co., Ltd. Cyclic amino benzoic acid derivative
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
DK1954684T3 (da) 2005-11-15 2014-06-30 Otsuka Pharma Co Ltd Oxazol forbindelse og farmaceutisk sammensætning.
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
CA2643796A1 (en) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. Polycyclic cinnamide derivatives
US8598168B2 (en) 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
SI2014652T1 (sl) 2006-04-18 2014-12-31 Nippon Chemiphar Co., Ltd. Aktivacijsko sredstvo za peroksisomski proliferatorski aktivirani receptor
KR101130380B1 (ko) 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
EP2054411B1 (en) 2006-07-27 2014-08-20 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
PL2090570T3 (pl) 2006-09-05 2012-03-30 Kyowa Hakko Kirin Co Ltd Pochodna imidazolu
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
CN101711154A (zh) 2007-02-26 2010-05-19 科森生物科学公司 氨基甲酸酯化合物
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2176228A1 (en) * 2007-07-04 2010-04-21 NeuroSearch A/S Novel pyrazole derivatives useful as potassium channel modulators
BR112012001098A2 (pt) 2009-07-09 2015-09-01 Crescendo Therapeutics Llc Método de cicatrização de feridas e modulação de cicatriz
WO2011069039A1 (en) * 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
AU2012207565B2 (en) 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
WO2013019561A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
DK3333164T3 (da) 2011-07-29 2023-09-18 Karyopharm Therapeutics Inc Hydrazide containing nuclear transport modulators and uses thereof
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
HUE042800T2 (hu) 2013-06-21 2019-07-29 Karyopharm Therapeutics Inc 1,2,4-triazolok mint nukleáris transzport modulátorok és ezek alkalmazása
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2015073908A1 (en) 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method for selecting cancer treatment regimen
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
AU2015301484B2 (en) 2014-08-15 2020-02-20 Karyopharm Therapeutics Inc. Polymorphs of selinexor
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
US10993943B2 (en) 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
CO7190242A2 (es) 2015-02-19
US10058535B2 (en) 2018-08-28
CL2014003054A1 (es) 2015-05-15
BR112014027860B1 (pt) 2022-03-08
EP2858991A2 (en) 2015-04-15
US9266843B2 (en) 2016-02-23
US20200038373A1 (en) 2020-02-06
AU2018201012B2 (en) 2019-12-05
KR20200041986A (ko) 2020-04-22
LT2858991T (lt) 2018-11-26
US20210251968A1 (en) 2021-08-19
PL3404027T3 (pl) 2020-09-21
SI2858991T1 (sl) 2018-12-31
EA201492050A1 (ru) 2015-07-30
MX364992B (es) 2019-05-17
DK3404027T3 (da) 2020-06-02
US20160354347A1 (en) 2016-12-08
US20130317031A1 (en) 2013-11-28
AU2016222459A1 (en) 2016-09-22
CA2872190A1 (en) 2013-11-14
US20160145246A1 (en) 2016-05-26
JP2018012715A (ja) 2018-01-25
ES2702279T3 (es) 2019-02-28
EP2858991B1 (en) 2018-08-08
PL2858991T3 (pl) 2019-01-31
EP3404027B1 (en) 2020-03-04
ES2794866T3 (es) 2020-11-19
PE20150128A1 (es) 2015-02-23
PT2858991T (pt) 2018-12-17
US20200230110A1 (en) 2020-07-23
JP2021063104A (ja) 2021-04-22
JP6818849B2 (ja) 2021-01-20
US20170319551A1 (en) 2017-11-09
KR20200115688A (ko) 2020-10-07
US20180289675A1 (en) 2018-10-11
US9585874B2 (en) 2017-03-07
BR112014027860B8 (pt) 2024-04-30
AU2019272017B2 (en) 2021-05-27
US11318120B2 (en) 2022-05-03
GEP20237477B (en) 2023-03-27
NZ702663A (en) 2017-03-31
JP2020037585A (ja) 2020-03-12
US9861614B2 (en) 2018-01-09
AU2021221398A1 (en) 2021-09-16
KR20200041984A (ko) 2020-04-22
JP2018172444A (ja) 2018-11-08
AU2019272017A1 (en) 2019-12-19
HRP20181838T1 (hr) 2018-12-28
EP3404027A1 (en) 2018-11-21
EP3663291A1 (en) 2020-06-10
ES3016982T3 (en) 2025-05-12
KR102165177B1 (ko) 2020-10-13
KR20200118240A (ko) 2020-10-14
KR102163377B1 (ko) 2020-10-08
LT3404027T (lt) 2020-07-10
PT3404027T (pt) 2020-03-30
DK2858991T3 (en) 2018-11-26
HRP20200876T1 (hr) 2020-09-04
US20150111893A1 (en) 2015-04-23
HK1209420A1 (en) 2016-04-01
CY1120832T1 (el) 2019-12-11
SMT201800686T1 (it) 2019-01-11
CN104428295B (zh) 2017-08-08
US10722497B2 (en) 2020-07-28
SMT202000347T1 (it) 2020-07-08
RS60424B1 (sr) 2020-07-31
CN104428295A (zh) 2015-03-18
EP3663291B1 (en) 2024-12-18
US20190008833A1 (en) 2019-01-10
EA036639B1 (ru) 2020-12-02
US9096543B2 (en) 2015-08-04
BR112014027860A2 (pt) 2017-06-27
KR20150018809A (ko) 2015-02-24
SG11201407268SA (en) 2015-01-29
HUE050452T2 (hu) 2021-03-29
AU2013259384B2 (en) 2016-06-02
WO2013170068A3 (en) 2014-02-20
AU2013259384A1 (en) 2014-12-18
WO2013170068A2 (en) 2013-11-14
JP6195909B2 (ja) 2017-09-13
US10617677B2 (en) 2020-04-14
US10335393B2 (en) 2019-07-02
CY1123476T1 (el) 2022-03-24
IN2014DN09434A (OSRAM) 2015-07-17
HUE040427T2 (hu) 2019-03-28
CA2872190C (en) 2024-06-25
KR102095429B1 (ko) 2020-03-31
SI3404027T1 (sl) 2020-08-31
US10925859B2 (en) 2021-02-23
AU2018201012A1 (en) 2018-03-01
AU2021221398B2 (en) 2023-08-17
ZA202004892B (en) 2023-03-29
KR102223028B1 (ko) 2021-03-03
UA118085C2 (uk) 2018-11-26
MX2014013551A (es) 2015-01-16
RS58058B1 (sr) 2019-02-28
ME03795B (me) 2021-04-20
JP2015516434A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
UA124922C2 (uk) Модулятори ядерного транспорту та їх застосування
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
PH12017501306A1 (en) Inhibitors of histone demethylases
IN2015DN01156A (OSRAM)
UA109010C2 (en) Morpholino pyrividines and their use in therapy
PH12015502615B1 (en) Chemical compounds
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MX378433B (es) Moduladores del transporte nuclear que contienen hidrazida y sus usos
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
PH12015501609A1 (en) Phenicol antibacterials
MX392150B (es) Moduladores de receptores canabinoides.
EA201590562A1 (ru) Бензамиды
MX2015004362A (es) Derivados de ketamina.
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
MX2014001862A (es) 5-cicloalquil-o 5-heterociclil-nicotinamidas.
IN2013MU01252A (OSRAM)
IN2013MU01251A (OSRAM)
UA112586C2 (uk) Похідні бензімідазолпроліну